Updated October 3, 2012, at 9:45 p.m. to correct the lead story.
MASSDEVICE ON CALL — The 1st reports from a global registry evaluating Edwards Lifesciences’ (NYSE:EW) Sapien transcatheter aortic valve implantation inside a failing valve or mitral ring came with mixed results.*
The Sapien TAVI valve-in-valve procedure proved effective after 1 year, but in-hospital mortality proved a significant issue, affecting 10 of 91 patients, TheHeart.org reported.
"These deaths were mostly related to access-site bleeding and other major life-threatening bleeding events like tamponade," investigator Dr. Danny Dvir told the news site. "I hope that this is related to a learning-curve issue and that when many of the sites gain more experience doing these procedures we will see better early results.
Israeli device maker opens doors in Massachusetts
Isreal’s Argo Medical Technologies plans to open a new headquarters in Marlborough, Mass., where the "exoskeleton" maker will hire up to 40 employees to work on the walking assistance technology for paraplegics.
Patients, doctors and the Twitterverse
Patients put a lot of stock in health messages tweeted by doctors with a sizable reputation on Twitter, but pay less attention to re-tweets, according to researchers.
*Correction, October 3, 2012: Due to a reporter’s error, the lead story inacurately reported the clinial study evaluating the Sapien TAVI to compare TAVI with open surgery.